On 7 April in Geneva, IFPMA delivered a statement at the 13th resumed meeting of the INB to agree a WHO instrument for pandemic prevention, preparedness, and response.

The biopharmaceutical industry is pivotal in preparing for and responding to pandemics, driving the innovation necessary to develop pharmaceuticals and other critical products for future health crises.

To enhance pandemic preparedness and response, it is essential to focus on sustaining scientific research on pathogens with pandemic potential while ensuring equitable access to vaccines and treatments during a pandemic emergency. This goal can only be achieved through a strong intellectual property system that must be protected.

As stated in the Berlin Declaration and Equitable Access statements, the industry is dedicated to broadening access to its products during pandemic emergencies through various strategies, including donations, equity-based tiered pricing, voluntary licensing, and voluntary technology transfers on mutually agreed terms. The significance of including both “voluntary” and “on mutually agreed terms” for technology transfer is paramount, as it facilitates the sharing of technologies and expertise in a manner that respects the interests and agreements of all parties involved.

Different situations and countries may require diverse interventions at various stages of a pandemic emergency. Therefore, it is crucial to establish a flexible system that allows a wide range of companies to utilize their skills and expertise effectively.

To promote equitable access, we urge Member States to implement measures both before and during a pandemic to support healthcare systems, enhance surveillance mechanisms, streamline regulatory procedures, develop accurate forecasts, and ensure that companies receive the necessary orders to scale up production. By addressing these barriers, Member States can help ensure that life-saving innovations reach those in need. This preparedness and response system must function effectively at global, regional, and national levels.

We remain committed to sharing our knowledge and providing our expertise to support global health initiatives and strengthen pandemic preparedness and response.

About IFPMA

IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.

To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.

ifpma.org

Media Contact

Elliot Dunster e.dunster@ifpma.org